PLANTATION, Fla., April 14 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to present at the
Rodman & Renshaw 2nd Annual Global Healthcare Conference in Paris on May 5th.
President and CEO Charles A. Rice will provide an overview and discuss the
Company's drugs, technologies and collaborations.
Event: VRA Presentation at Rodman & Renshaw Global Healthcare Conference
When: Thursday, May 5 at 10:50 a.m. (Local Paris Time)
Where: Intercontinental Hotel, Paris, France
To Register: Please visit http://www.rodmanandrenshaw.com
A live webcast of the presentation can be accessed through Viragen's
website at http://www.Viragen.com and an archived replay will be made
available.
"Based on commercial, scientific and partnering achievements that we
expect to announce this year, we intend to proactively communicate our
progress and prospects at events such as the upcoming Rodman & Renshaw
conference," stated Mr. Rice. "Additionally, we will be conducting a series
of targeted institutional investor road shows with the first to commence at
the end of this month."
About Rodman & Renshaw, LLC:
Rodman & Renshaw, LLC is a privately held, full-service investment bank
committed to fostering the long-term success of emerging growth companies
through capital raising, strategic advice, insightful research, and the
development of institutional support. During the last two years, Rodman &
Renshaw completed over 60 financing transactions, totaling over $1 billion.
Rodman & Renshaw concentrates on emerging growth companies in the life science
and technology sectors.
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include Multiferon(R) (natural human alpha interferon),
monoclonal antibodies and a peptide drug. Viragen's strategy also includes
the development of Avian Transgenic Technology as a biomanufacturing platform
for the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made. Guests scheduled to present at this event are
potentially subject to be replaced, rescheduled or canceled due to unforeseen
conflicts.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
http://www.rodmanandrenshaw.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
